ArticleAnalytical and bioanalytical chemistry2025
Self-assembled aggregation-induced emission supramolecular probe for sensitive temozolomide detection and intracellular imaging.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Temozolomide (TMZ) is a first-line chemotherapy drug for treating malignant glioblastoma but faces challenges due to its short plasma half-life and limited brain distribution. There is a need for a more efficient, cost-effective, and sensitive method for monitoring TMZ in clinical settings. This work presents a novel fluorescent probe based on the host-guest interaction of cucurbit[7]uril (CB[7]) and aggregation-induced emission molecule 1,1,2,2-tetra(biphenyl-4-yl)ethene (TTPE) for trace-level detection of TMZ in serum. The CB[7]@TTPE nanoprobe demonstrated high sensitivity, with a detection range of 1-20 μg/mL and a limit of detection of 0.25 μg/mL. Comprehensive characterization by ITC, FT-IR, NMR, UV-vis, and fluorescence spectroscopy confirmed the sensing behavior of the probe. The system exhibited excellent selectivity for TMZ and was successfully applied to serum samples with good recovery rates. In addition, the probe enabled fluorescence imaging of TMZ in human glioma cells (U87 and T98G), making it suitable for monitoring of drug distribution in cellular environments. The self-assembled CB[7]@TTPE probe provides a highly sensitive and selective method for TMZ detection in biological fluids. Its strong fluorescence and water solubility offer promising potential for both clinical diagnostics and drug resistance monitoring in cancer therapy.
Indexed as
Identifiers
40804284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.